Study of Predictive Immunological Parameters of Molecular Complete Remission in Patients With Chronic Myelogenous Leukemia in Chronic Phase and Treated With Tyrosine Kinase Inhibitor

NCT02842333 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Chronic Leukemia

Interventions

OTHER: Additional biological samples

Sponsor

Centre Hospitalier Universitaire de Besancon